- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04405544
Determination of Acute Encephalopathy Predictors in Patients With COVID-19
The SARS-CoV-2 infection was detected in December 2019 in Wuhan City, China. The infection affects all age groups, although childhood is the lowest proportion of those affected.
The main clinical manifestations that require hospitalization of infected patients are SARS pneumonia, which may require treatment in the intensive care unit (27%) and its progression into acute respiratory distress syndrome (67%) with life-threatening conditions in almost 25% of patients diagnosed with "SARS-CoV-2 infection".
Nervous system damage with SARS-CoV-2 infection has been practically not investigated, but neurological disorders have been reported in 36% of these patients.
Finally, the mortality rate associated with the new virus is high in patients who require treatment in intensive care units (62% of cases).
Therefore, we are conducting a prospective study to identify acute encephalopathy predictors in patients with COVID-19.
Study Overview
Status
Conditions
Detailed Description
This is a prospective, cohort-based, adaptive design study that aims to identify acute encephalopathy predictors in patients with COVID-19. Patients with community-acquired pneumonia and confirmed pulmonary tissue infiltration will be enrolled in the study based on CT data with changes corresponding to the medium and high probability of coronavirus pneumonia (CO-RADS 4-5) and lesion of at least 25% of one lung.
Each patient will be examined at least twice (2 visits): P1 - on admission to hospital; P2 - in 10±5 days.
In the further course of the disease patients will be divided into 2 groups (cohorts). Group 1 - patients who have developed acute encephalopathy. Group 2 - patients who at the moment of discharge have no acute encephalopathy.
The study will collect clinical exam ( including neurological signs), neurophysiological data (including electroencephalography (EEG) and evoked potential (EP)), comprehensive laboratory tests, CT-scan and all standards of care to identify predictors of acute encephalopathy.
The study will consist of two phases:
The pilot phase - inclusion of the first 60 patients, followed by an interim analysis on the basis of which will be clarified:
- sample size;
- clinical, laboratory and instrumental parameters to be analyzed;
- terms and frequency of the EEG and EP.
- The main phase - further patient recruitment and all procedures required by the protocol.
The intermediate and final analysis will include both patients who have developed acute encephalopathy (main group) and patients who have not developed acute encephalopathy (control group).
Acute encephalopathy will be defined as recently stated :
- The term acute encephalopathy refers to a rapidly developing (over less than 4 weeks, but usually within hours to a few days) pathobiological process in the brain. This is a preferred term
- Acute encephalopathy can lead to a clinical presentation of subsyndromal delirium, delirium, or in case of a severely decreased level of consciousness, coma; all representing a change from baseline cognitive status
- The term delirium refers to a clinical state characterized by a combination of features defined by diagnostic systems such as the DSM-5.
Delirium according to the DSM-5 is defined if criterium A-E are fulfilled:
A. Disturbance in attention (i.e., reduced ability to direct, focus, sustain, and shift attention) and awareness (reduced orientation to the environment).
B. The disturbance develops over a short period of time (usually hours to a few days) represents a change from baseline attention and awareness, and tends to fluctuate in severity during the course of the day.
C. An additional disturbance in cognition (e.g., memory deficit, disorientation, language, visuospatial ability, or perception).
D. The disturbances in criteria A and C are not explained by another pre-existing, established, or evolving neurocognitive disorder, and do not occur in the context of a severely reduced level of arousal, such as coma.
E. There is evidence from the history, physical examination, or laboratory findings that the disturbance is a direct physiologic consequence of another medical condition, substance intoxication or withdrawal (i.e. because of a drug of abuse medication), or exposure to a toxin, or is because of multiple etiologies [1].
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Moscow, Russian Federation, 105203
- N.I. Pirogov National Medical and Surgical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women aged 18 to 60 years
- Out-of-hospital pneumonia with confirmed pulmonary tissue infiltration according to CT with changes corresponding to the average and high probability of coronavirus pneumonia (4-5 levels by CO-RADS classification) and the loss of more than 25% of one of the lungs.
- The patient has read the information sheet and signed the informed consent form.
Exclusion Criteria:
- Negative PCR test for coronavirus infection.
- The presence in the anamnesis of data for myocardial infarction or stroke.
- Verified thrombophilia.
- Pregnancy.
- Patients with malignant tumors (including anamnesis), including postoperative period in the background of chemo and/or radiation therapy.
- Acute stroke.
Dropout Criteria:
- Patient's refusal to participate further in the study.
- Negative PCR result for coronavirus infection.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: Main
patients with COVID-19 and Acute Encephalopathy
|
chest CT-scan
Electroencephalography
Evoked potential
Pulse oximetry
Blood tests
|
OTHER: Control
patients with COVID-19 without Acute Encephalopathy
|
chest CT-scan
Electroencephalography
Evoked potential
Pulse oximetry
Blood tests
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The percentage of patients who have developed encephalopathy
Time Frame: 10 days
|
The percentage of patients who have developed encephalopathy
|
10 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Oleg I Vinogradov, MD, PhD, N.I. Pirogov National Medical and Surgical Center
Publications and helpful links
General Publications
- Slooter AJC, Otte WM, Devlin JW, Arora RC, Bleck TP, Claassen J, Duprey MS, Ely EW, Kaplan PW, Latronico N, Morandi A, Neufeld KJ, Sharshar T, MacLullich AMJ, Stevens RD. Updated nomenclature of delirium and acute encephalopathy: statement of ten Societies. Intensive Care Med. 2020 May;46(5):1020-1022. doi: 10.1007/s00134-019-05907-4. Epub 2020 Feb 13. No abstract available.
- Vinogradov OI, Ogarkova TK, Shamtieva KV, Alexandrov PV, Mushba AV, Kanshina DS, Yakovleva DV, Surma MA, Nikolaev IS, Gorst NK. Predictors of Acute Encephalopathy in Patients with COVID-19. J Clin Med. 2021 Oct 20;10(21):4821. doi: 10.3390/jcm10214821.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NMSC-01-20
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID
-
European Institute of OncologyFondazione I.R.C.C.S. Istituto Neurologico Carlo Besta; Azienda Ospedaliera... and other collaboratorsCompleted
-
Owlstone LtdCambridge University Hospitals NHS Foundation TrustCompleted
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Sultan Qaboos UniversityCompletedCOVID-19 | Non-CovidOman
-
Assiut UniversityRecruiting
-
Jilin UniversityUnknown
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Miami VA Healthcare SystemNot yet recruiting
Clinical Trials on CT-scan
-
Amsterdam UMC, location VUmcMRIguidance B.V.CompletedSinusitis | Hearing Loss | Head and Neck Tumor | Cholesteatoma | Imaging of Bony Structures of the Head (Various Conditions)Netherlands
-
University Hospital, AntwerpCompleted
-
ElsanRecruitingTotal Occlusion of Coronary ArteryFrance
-
University of RochesterNational Cancer Institute (NCI)Completed
-
Fondazione Policlinico Universitario Agostino Gemelli...Enrolling by invitationAortic Valve Stenosis | Heart Valve Diseases | Aortic Regurgitation | Aortic Valve Insufficiency | Aortic Stenosis, Severe | Regurgitation, Aortic | Stenoses, Aortic | Coronary; Obstruction | Valve Disease, AorticItaly
-
European Institute of OncologyAssociazione Italiana per la Ricerca sul CancroCompletedSubjects at High Risk of Lung Cancer Due to SmokingItaly
-
Ontario Clinical Oncology Group (OCOG)Ontario Ministry of Health and Long Term CareCompletedAdenocarcinoma | Cervical Cancer | Squamous Cell Carcinoma | Adenosquamous CarcinomaCanada
-
University Hospital AugsburgRecruitingNeoplasms | Neoplasm Metastasis | Metastatic CancerGermany
-
NureaWithdrawn
-
NureaCompletedAortic AneurysmFrance